Monogenic forms of childhood obesity due to mutations in the leptin gene by unknown
Funcke et al. Molecular and Cellular Pediatrics 2014, 1:3
http://www.molcellped.com/content/1/1/3REVIEW Open AccessMonogenic forms of childhood obesity due to
mutations in the leptin gene
Jan-Bernd Funcke1, Julia von Schnurbein1, Belinda Lennerz1, Georgia Lahr2, Klaus-Michael Debatin2,
Pamela Fischer-Posovszky1 and Martin Wabitsch1*Abstract
Congenital leptin deficiency is a rare autosomal recessive monogenic obesity syndrome caused by mutations in the leptin
gene. This review describes the molecular and cellular characteristics of the eight distinct mutations found so far in humans.
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During the last four decades, the prevalence of obesity in
childhood has increased dramatically and obesity has be-
come an epidemic disease with more than 5% of all children
affected in developed countries [1]. Changes in living condi-
tions may act on children's behavior and favor the develop-
ment of obesity due to individual genetic susceptibility [1].
In the vast majority of obese children, no syndromal
or monogenic cause for the obese state can be diagnosed
and therefore a polygenic cause is suggested. Generally,
monogenic forms of childhood obesity are very rare [2].
Mutations in only a few genes are known to cause the
development of severe obesity in early childhood [2].
Most of these genes are involved in the central nervous
regulation of hunger and satiety where the leptin/leptin
receptor system plays a pivotal role [3]. Of all mono-
genic forms of obesity, the only one causally treatable is
congenital leptin deficiency caused by homozygous mu-
tations of the leptin gene [4]. Leptin is a protein secreted
mainly by adipocytes, and its circulating levels correlate
positively with the body mass index and the body fat
mass. By central as well as peripheral action, leptin im-
pacts diverse physiological processes including energy
balance, metabolism, endocrine regulation, and immune
function [3]. One of the main functions of leptin is to
control the body fat mass by inhibiting food intake via
the central nervous system. Recombinant human* Correspondence: martin.wabitsch@uniklinik-ulm.de
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in any medium, provided the original work is pleptin (metreleptin) can be administered to patients
with congenital leptin deficiency to compensate the
lack of leptin [5].
Current clinical recommendations suggest that chil-
dren with a normal birth weight but rapid weight gain in
the first few months of life leading to extreme obesity
should be tested for congenital leptin deficiency when
they show impaired satiety, intense hyperphagia, and
food-seeking behavior (see Clinical phenotype of pa-
tients with congenital leptin deficiency) [6,7]. Most pa-
tients described up to now had consanguine parents.
Patients usually develop metabolic and hormonal alter-
ations including hyperinsulinemia, insulin resistance, severe
liver steatosis, dyslipidemia, as well as hypogonadotropic
hypogonadism (see Clinical phenotype of patients with
congenital leptin deficiency) [7,8]. Furthermore, some pa-
tients display immunological alterations in early childhood
that manifest in recurrent severe bacterial infections pos-
sibly resulting in death in childhood (see Clinical phenotype
of patients with congenital leptin deficiency) [4]. Upon sub-
stitution therapy with recombinant human leptin applied
by daily subcutaneous injections, patients lose weight, the
body fat mass is reduced, and the metabolic, hormonal, and
immunological abnormalities are normalized [4,8,9].
Clinical phenotype of patients with congenital leptin
deficiency
Normal birth weight
Rapid weight gain after birth
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Constant food-seeking behavior
Recurrent severe and possibly lethal bacterial infections
in early childhood (some patients)
Development of hyperinsulinemia
Development of severe liver steatosis
Development of dyslipidemia
Hypogonadotropic hypogonadism
In humans, eight distinct leptin mutations have been
described in the literature, which lead to congenital lep-
tin deficiency when present in the homozygous state. On
the cellular level, these mutations result in defects in the
synthesis and/or secretion of leptin. In the following par-
agraphs, we have summarized the molecular and cellular
characteristics of these mutations.
Review
Leptin gene and protein structure
The gene encoding leptin (LEP or OB) was discovered
by positional cloning in 1994 [10]. The LEP gene is located
on chromosome 7q31.3 and consists of three exons sepa-
rated by two introns [11] [Ensembl:ENSG00000174697].
Leptin is a type I cytokine and member of the family
of long-chain helical cytokines which also includes in-
terleukin 6 (IL-6), granulocyte colony-stimulating factor
(G-CSF), and growth hormone (GH) [12]. It is synthe-
sized as an immature 167-amino acid protein encom-
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Figure 1 Overview of human leptin mutants. Mapping of the eight dist
and immature as well as mature leptin protein. Where applicable, the sizes
acids (aa). For the leptin gene, exons are depicted as filled boxes while intr
exon 2 and exon 3 that form the open reading frame (ORF) are colored in
region (UTR) are colored in a lighter shade while the ORF is colored in a da
gets cleaved off during the maturation process is colored in a darker shade
consistent with the HGVS recommendations. All sequence information is b[Ensembl:ENST00000308868]. Cleavage of the signal pep-
tide yields a non-glycosylated, mature 146-amino acid
protein [10] [Ensembl:ENST00000308868]. Its structure
features four major α helices A to D as well as a distorted
minor α helix E, localized in the loop connecting helices C
and D [12]. Assuming an up-up-down-down orientation,
the helices A to D form a four-helix bundle which is stabi-
lized by a single intramolecular disulfide bond spanning
from the beginning of the loop between helices C and D
to the C-terminus of the protein [12].
Molecular and cellular characteristics of human leptin
mutants
The notation used to describe the position and character
of human leptin mutations has been inconsistent up to
now [13-23]. Therefore, we provide a consistent notation
and overview of the eight distinct leptin mutations de-
scribed in humans so far (Figure 1) mapped to the hu-
man leptin gene, transcribed leptin mRNA (here cDNA),
and translated immature and processed mature leptin
protein. In the text of this review, the given position
of amino acids in the leptin protein uniformly refers
to their position in the unprocessed, immature protein.
Moreover, we have summarized information about the
eight known leptin mutations in humans, including the
number of patients reported to carry these mutations
(Table 1). Unless otherwise indicated, the chosen nomen-
clature adheres to the recommendations of the Human




















inct human leptin mutations to the human leptin gene, leptin cDNA,
of individual portions are given either in base pairs (bp) or amino
ons and flanking regions are depicted as thin lines. The portions of
a darker shade. For the leptin cDNA, the 5′ and the 3′ untranslated
rker shade. For the immature leptin protein, the signal peptide that
. For the mature leptin protein, the chosen nomenclature is not
ased on [Ensembl:ENSG00000174697, Ensembl:ENST00000308868].
Table 1 Summary of patients reported to carry leptin mutations






Female, 8 years 0.1 to 1.0 ng/ml (close to detection limit) Montague et al. [13]
Male, 2 years 0.4 to 0.7 ng/ml (close to detection limit)
Male, 3 years Below detection limit Farooqi et al. [5]
Female, 5 years Below detection limit Gibson et al. [24]
Gender and age not specified Not reported Farooqi [25]
Gender and age not specified Not reported
Gender and age not specified Not reported
Female, 5 months Below detection limit Fatima et al. [21]
Female, 2 years 0.1 ng/ml
Female, 2 years Below detection limit
Female, age not specified Below detection limit
Female, age not specified Below detection limit
Male, 1 year 0.5 ng/ml
Male, 7 years Below detection limit
Male, 7 years Below detection limit
Male, 12 years Below detection limit
Female, 8 months 0.8 ng/ml Saeed et al. [22]
Female, 8 months 1.0 ng/ml
Female, 8 months Below detection limit
Female, 2 years Below detection limit
Male, 8 months Below detection limit
Male, 1 year 0.5 ng/ml
Male, 1 year 5 months 0.7 ng/ml
Male, 3 years 4 months 0.7 ng/ml
Male, 7 years 0.9 ng/ml
Female, age not specified Below detection limit Saeed et al. [26]
Female, age not specified Below detection limit
Female, age not specified Below detection limit
Female, age not specified Below detection limit






Female, 6 years 1.1 ng/ml Strobel et al. [15]
Female, 34 years 1.3 to 1.6 ng/ml
Male, 22 years 0.9 to 1.2 ng/ml
Female, 30 years 0.6 ng/ml Ozata et al. [27]






Gender and age not specified Not reported Chekhranova et al. [17]






Female, 7 years 1.3 ng/ml Mazen et al. [18]
Male, 3 years 1.1 ng/ml
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1 to 2 (probable overlap)
Female, 7 months 3.6 ng/ml Fatima et al. [21]












Female, 8 years <0.6 ng/ml Thakur et al. [23]
For the mature leptin protein, the chosen nomenclature is not consistent with the HGVS recommendations. All sequence information is based on
[Ensembl:ENSG00000174697, Ensembl:ENST00000308868].
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deficiency in humans was originally described in 1997 in
two children from a consanguineous Pakistani pedigree
[13]. A deletion of the guanine at position 13374 of the
leptin gene (g.13374delG) corresponding to position 398
of the transcript (c.398delG) led to a frameshift mutation
of the protein. This changed the glycine at position 133
to a valine and inserted additional 13 subsequent aberrant
amino acids before coming to a stop (p.G133Vfs*15) [13].
In both patients, the serum leptin levels as measured by a
radioimmunoassay (RIA) and enzyme-linked immuno-
sorbent assay (ELISA) were close to the detection limit
(1.0 and 0.7 ng/ml by RIA as well as 0.1 and 0.4 ng/ml
by ELISA, respectively) [13]. Furthermore, in one of the
patients, no leptin could be detected in the serum by
Western blot [13]. Transfecting CHO cells with a plasmid
encoding p.G133Vfs*15 leptin showed that p.G133Vfs*15
leptin is synthesized, but not secreted to the cell culture
supernatant [13]. Montague et al. proposed two mecha-
nisms responsible for the low serum leptin levels observed
in the patients [13]. First, the introduction of a premature
stop codon into the transcript might cause nonsense-
mediated mRNA decay (NMD) [13]. Second, the intro-
duction of an aberrant stretch of amino acids into the
protein might cause improper intracellular transport and
secretion [13]. A subsequent detailed study using CHO
and COS-7 cells revealed that p.G133Vfs*15 leptin indeed
exhibits an improper intracellular transport, aggregates
and accumulates in the ER, and subsequently undergoes
degradation by the proteasome [14].
In 1998, a second mutation conferring a congenital de-
ficiency in leptin was described in three individuals from
a consanguineous Turkish pedigree [15]. A transition of
the cytosine at position 13289 of the leptin gene to a
thymine (g.13289C>T) corresponding to position 313of the transcript (c.313C>T) led to a missense mutation
of the protein, changing the arginine at position 105 to a
tryptophan (p.R105W) [15]. The serum leptin levels as
assessed by two different immunoassays were very low
in all three patients (1.6, 0.9, and 1.1 ng/ml by the first
assay as well as 1.3, 1.2, and 1.1 ng/ml by the second as-
say, respectively) [15]. Transfecting COS-1 cells, Strobel
et al. showed that like p.G133Vfs*15 leptin, p.R105W
leptin is synthesized but not secreted [15]. They con-
sequently assumed that the mutant leptin displays a
normal synthesis and stability, but aberrant intracellular
transport and impaired secretion [15]. Two subsequent
studies employing in vitro-differentiated PAZ6 adipocytes,
primary rat adipocytes, as well as CHO and COS-1 cells
confirmed that p.R105W leptin indeed misfolds, aggre-
gates, and accumulates intracellularly [14,16]. In wild-type
leptin, p.R105 is surrounded by negatively charged amino
acids and forms salt bridges with p.D76 and p.E102 [16].
Boute et al. proposed that the p.R105W mutation might
induce protein misfolding by disrupting the formation
of these salt bridges [16]. Transfecting COS-1 cells and
in vitro-differentiated PAZ6 adipocytes with plasmids en-
coding p.C117S, p.C167S, or p.C117S/C167S leptin, these
authors were furthermore able to demonstrate that the
correct formation of the intramolecular disulfide bond
is a prerequisite for the proper folding, intracellular
transport, and secretion of leptin [16]. Boute et al. conse-
quently proposed that the p.R105W mutation might alter-
natively induce protein misfolding by sterically interfering
with the proper formation of this intramolecular disulfide
bond [16].
A third mutation was described in 2008 in two indivi-
duals from a population inhabiting a small Turkmenian
mountain village [17]. A transversion of the cytosine
at position 13398 of the leptin gene to a guanine
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script (c.422C>G) led to a missense mutation of the
protein, changing the serine at position 141 to a cysteine
(p.S141C) [17]. No measurement of serum leptin levels
was reported in these patients [17]. Chekhranova et al.
proposed that the p.S141C mutation might result in pro-
tein misfolding and/or loss of biological activity by intro-
ducing a third cysteine into the protein, interfering with
the correct formation of the intramolecular disulfide
bond [17]. To our best knowledge, no study investi-
gating the synthesis or secretion of this mutant has
been published yet.
In 2009, a fourth mutation was described in two
children from a consanguineous Egyptian pedigree [18].
Here, a transversion of the cytosine at position 13285 of
the leptin gene to an adenine (g.13285C>A) correspond-
ing to position 309 of the transcript (c.309C>A) led to a
missense mutation of the protein, changing the aspa-
ragine at position 103 to a lysine (p.N103K) [18]. The
serum leptin levels were very low in both patients (1.1
and 1.3 ng/ml) [18]. Mazen et al. did not explicitly hy-
pothesize about how the p.N103K mutation might im-
pact the synthesis, secretion, or biological activity of the
protein [18]. Also in this case, no study examining the
synthesis or secretion of this mutant has been published
up to now. Notably though, the biological activity of this
mutant was nonetheless addressed by an in vitro study
performed by Niv-Spector et al. [19]. They made use of
a prokaryotic expression system to produce p.N103K
leptin and demonstrated that the p.N103K mutation
drastically reduces the biological activity of the protein
[19]. While they do not provide insight into the mecha-
nisms underlying the defective synthesis and/or secre-
tion of the mutant protein, they claim that not only the
very serum levels but also the biological inactivity of the
p.N103K leptin may contribute to the phenotype ob-
served in affected patients [19].
A fifth mutation was described by our group in 2010
in a child from an Austrian pedigree without known con-
sanguinity [20]. A transition of the thymine at position
13191 of the leptin gene to cytosine (g.13191T>C) corre-
sponding to position 215 of the transcript (c.215T>C) led
to a missense mutation of the protein, changing the leu-
cine at position 72 to a serine (p.L72S) [20]. In this pa-
tient, the serum leptin levels as measured by an RIA were
at the detection limit (0.4 ng/ml) [20]. Moreover, no leptin
could be detected in the serum of this patient by immuno-
precipitation and subsequent Western blot [20]. Analyzing
patient-derived adipose tissue, expression of the mutant
protein could be detected in adipocytes by qRT-PCR,
Western blot, as well as immunohistochemistry [20].
Furthermore, in vitro-differentiated patient-derived adi-
pocytes showed expression of the mutant protein [20].
Transfecting HEK293 cells confirmed that p.L72S leptinindeed is synthesized, but not secreted [20]. By genera-
ting plasmids encoding p.L72A, p.L72I, p.L72V, or p.L72T
leptin and transfecting these plasmids into HEK293 cells,
our group was able to determine the lack of side chain
hydrophobicity at position 72 of the protein as the main
cause for the lack of secretion [20].
A sixth and a seventh mutation were originally de-
scribed in 2011 in individuals stemming from consan-
guineous Pakistani pedigrees [21]. In a child, a deletion
of a thymine-cytosine-adenine triplet at positions 10839
to 10841 of the leptin gene (g.10839_10841delTCA) cor-
responding to positions 104 to 106 of the transcript, re-
spectively, (c.104_106delTCA) was detected [21]. This in
turn resulted in the deletion of the isoleucine at position
35 of the protein (p.I35del) [21]. In this patient, Fatima
et al. originally observed low, but still detectable serum
leptin levels as measured by an ELISA (3.6 ng/ml) [21].
In a later publication, Saeed et al. also reported a child
with a p.I35del mutation, probably the very same pa-
tient, in which they could not detect any leptin in the
serum using an ELISA [22]. Fatima et al. hypothesized
that the deletion of this highly conserved isoleucine at
position 35 of the protein and thus resulting loss of
hydrophobicity in the N-terminal region of the protein
might result in defective intracellular transport and
secretion [21]. Furthermore, these authors proposed
that the p.I35del mutation might also result in a loss of
the biological activity of the secreted protein as the N-
terminal region of leptin has been proposed to be involved
in the binding of leptin to the leptin receptor [21].
In another child, a deletion of a cytosine-thymine
doublet at positions 13457 and 13458 of the leptin gene
(g.13457_13458delCT) corresponding to positions 481
and 482 of the transcript (c.481_482delCT) led to a
frameshift mutation of the protein, changing the leucine
at position 161 of the protein to a glycine and inserting
additional eight subsequent aberrant amino acids before
coming to a stop (p.L161Gfs*10) [21]. In this patient, the
serum leptin level as measured by an ELISA was very
low (0.2 ng/ml) [21]. Fatima et al. proposed that in the
case of the p.L161Gfs*10 mutation, the loss of the C-
terminal p.C167 and thus resulting loss of the intramo-
lecular disulfide bond as well as the introduction of an
aberrant stretch of amino acids might result in misfold-
ing, impaired intracellular transport and secretion, as
well as a loss of the biological activity of the secreted
protein [21]. No study examining the synthesis or secre-
tion of either the p.I35del or the p.L161Gfs*10 mutant
has been published up to now.
Only recently, in 2013, an eighth mutation was de-
scribed in a child from a consanguineous Indian pedi-
gree [23]. Here, a transition of the cytosine at position
13139 of the leptin gene to thymine (g.13139C>T) corre-
sponding to position 163 of the transcript (c.163C>T)
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the glutamine at position 55 to a stop (p.Q55*) [23].
The serum leptin levels in this patient were very low
(<0.6 ng/ml) [23]. Thakur et al. did not explicitly hy-
pothesize about how the introduction of an early prema-
ture stop codon into the mutant transcript might impact
the synthesis, secretion, or biological activity of the protein
[23]. As with the p.G133Vfs*15 and p.L161Gfs*10 mu-
tants, NMD should definitely be considered as a possible
mechanism causative of the very low serum leptin levels
observed with this mutant. Again, to our best knowledge,
no study investigating the synthesis or secretion of this
mutant has been published as of now.Existence of novel biologically inactive human leptin
mutants veiled by unsuspicious serum leptin levels
As presented in the preceding paragraphs, the serum
leptin levels reported in the patients carrying homozy-
gous leptin mutations have been close to undetectable
or very low and thus out of proportion to the body fat
mass found in these patients, making these patients se-
verely leptin deficient [13,15,18,20-23].
A comparable situation is observed in leptin-deficient
obese (ob/ob) mouse strains, in which leptin was ori-
ginally discovered in 1994 [10,29]. In the ob1J strain, a
transition of the cytosine at position 12850 of the lep-
tin gene to thymine (g.12850C>T) corresponding to
position 313 of the transcript (c.313C>T) leads to a
nonsense mutation of the protein, converting the ar-
ginine at position 105 to a stop (p.R105*) [10] [Ensembl:
ENSMUSG00000059201, Ensembl:ENSMUST0000006
9789]. In this strain, the abundance of the leptin tran-
script in adipose tissue is drastically increased, while no
corresponding leptin protein can be found in the serum,
arguing for the synthesis of a mutant protein affected by
an impaired intracellular transport and secretion [10,30].
In contrast, in the ob2J strain, the insertion of a retroviral-
like transposon featuring several splice acceptor and poly-
adenylation sites into the first intron of the leptin gene
results in the generation of chimeric transcripts and con-
sequently no leptin protein synthesis at all [10,29].
Most strikingly, by far, not all known murine leptin mu-
tants exhibit a defective leptin synthesis and/or secretion.
N-ethyl-N-nitrosourea (ENU)-driven mutagenesis led
to the generation of a leptin-mutant mouse strain dis-
playing a coexistence of high serum leptin levels and a
phenotype very similar to that of the obese mouse strains
[30]. In this strain, a missense mutation of the leptin
protein changing the valine at position 145 to a glu-
tamate (p.V145E) was detected, which was caused by
a transversion of the thymine at position 12971 of the
leptin gene to an adenine (g.12971T>A) corresponding
to position 434 of the transcript (c.434T>A) [30][Ensembl:ENSMUSG00000059201, Ensembl:ENSMUST
00000069789].
In two extensive in vitro studies, Peelman et al. and
Iserentant et al. generated a large number of distinct
murine leptin mutants featuring either single or multiple
amino acid changes, essentially covering the whole sur-
face of the leptin protein [31,32]. Interestingly, using
COS-1 cells as a eukaryotic expression system, all mu-
tants except for those targeting p.L34 were found to be
synthesized and secreted to the cell supernatant, from
which they could be purified for further experiments
[31,32]. Several of these mutants showed pronounced
changes in their capacity to bind and/or activate the lep-
tin receptor, essentially proving that mutations rendering
murine leptin biologically inactive do not necessarily
have to affect leptin synthesis and/or secretion [31,32].
This raises the question whether forms of human con-
genital leptin deficiency exist, in which the production
of biologically inactive leptin is veiled by the presence of
unsuspicious or even elevated serum leptin levels.
Referring to current clinical recommendations, a se-
quencing of the leptin gene in patients with extreme
early-onset obesity is suggested only in the presence of
undetectable or very low serum leptin levels [6]. There-
fore, it cannot be excluded that cases of congenital leptin
deficiency with clearly detectable levels but bioinactive
hormone exist in humans.
Diseases caused by bioinactive hormones are very rare,
but still existent. For example, cases of biologically in-
active protein have been reported for hormones like
ACTH, TSH, as well as the leptin-related GH [33-36].
Therefore, the existence of congenital leptin dysfunction
should definitely be considered.Conclusions
Congenital leptin deficiency caused by homozygous mu-
tations in the leptin gene results in impaired satiety,
intense hyperphagia, and extreme early-onset obesity
accompanied by multiple metabolic, hormonal, and im-
munological abnormalities. In humans, eight distinct
leptin mutations characterized by undetectable to low
serum leptin levels have been identified so far. Mecha-
nistically, defects in the synthesis and/or secretion of
the hormone have been proposed and demonstrated for
some of these mutations. Affected patients can be suc-
cessfully treated with recombinant human leptin. Cur-
rent clinical recommendations suggest sequencing of
the leptin gene in cases of extreme early childhood obe-
sity preferably in the presence of undetectable to low
serum leptin levels. Thus, a change in practice might be
necessary to identify novel leptin mutations not showing
defects in the synthesis and secretion but in the bio-
logical activity of the hormone.
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